What is Zacks Research's Forecast for Palomar Q3 Earnings?

Key Points

• Zacks Research nudged down its Q3 2026 EPS estimate for Palomar to $2.57 (from $2.58) while maintaining a Strong-Buy rating and forecasting Q4 2026 EPS of $2.37 and FY2026 roughly $8.95 (consensus full-year ~$8.97).
• Palomar's most recent quarter beat estimates with $2.24 EPS (vs. $2.06 expected) and revenue of $253.36M (vs. $204.58M), representing revenue growth of 62.7% year-over-year and healthy profitability (net margin 22.5%, ROE 22.77%).
• Analyst views are mixed but average to Buy with a $161.75 price target, while insiders have sold 66,632 shares (~$8.18M) in the past 90 days and now own 3.7% of the company.

Palomar Holdings, Inc. (NASDAQ:PLMR - Free Report) - Research analysts at Zacks Research decreased their Q3 2026 earnings estimates for shares of Palomar in a research note issued on Friday, April 17th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $2.57 for the quarter, down from their prior forecast of $2.58. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Palomar's current full-year earnings is $8.97 per share. Zacks Research also issued estimates for Palomar's Q4 2026 earnings at $2.37 EPS, FY2026 earnings at $8.95 EPS and Q3 2027 earnings at $3.21 EPS.

Palomar (NASDAQ:PLMR - Get Free Report) last issued its earnings results on Wednesday, February 11th. The company reported $2.24 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.18. The company had revenue of $253.36 million for the quarter, compared to analysts' expectations of $204.58 million. Palomar had a net margin of 22.50% and a return on equity of 22.77%. The firm's revenue was up 62.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.52 EPS.

A number of other equities analysts have also recently commented on the stock. Weiss Ratings cut shares of Palomar from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, April 7th. Wall Street Zen cut shares of Palomar from a "buy" rating to a "hold" rating in a research report on Sunday, March 1st. Keefe, Bruyette & Woods lifted their target price on shares of Palomar from $183.00 to $186.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 7th. Evercore assumed coverage on shares of Palomar in a research report on Monday, February 9th. They issued an "outperform" rating and a $150.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Palomar from $155.00 to $160.00 and gave the company an "overweight" rating in a research report on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $161.75.

Palomar Stock Down 0.1%

Shares of NASDAQ:PLMR opened at $132.41 on Tuesday. The stock has a market cap of $3.51 billion, a PE ratio of 18.44 and a beta of 0.54. The company's fifty day moving average is $124.19 and its 200 day moving average is $124.22. Palomar has a 52 week low of $107.75 and a 52 week high of $175.85.

Insider Transactions at Palomar

In other Palomar news, President Jon Christianson sold 3,000 shares of the business's stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $125.00, for a total value of $375,000.00. Following the transaction, the president owned 62,919 shares in the company, valued at approximately $7,864,875. The trade was a 4.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Mac Armstrong sold 11,484 shares of the business's stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $119.88, for a total transaction of $1,376,701.92. Following the completion of the transaction, the chief executive officer owned 91,737 shares in the company, valued at $10,997,431.56. The trade was a 11.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 66,632 shares of company stock worth $8,177,085 in the last 90 days. Corporate insiders own 3.70% of the company's stock.

Hedge Funds Weigh In On Palomar

A number of hedge funds have recently modified their holdings of the company. Richardson Financial Services Inc. boosted its stake in shares of Palomar by 210.0% during the 3rd quarter. Richardson Financial Services Inc. now owns 217 shares of the company's stock valued at $25,000 after purchasing an additional 147 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in shares of Palomar during the 3rd quarter valued at about $25,000. Geneos Wealth Management Inc. bought a new stake in shares of Palomar during the 4th quarter valued at about $32,000. Kestra Advisory Services LLC bought a new stake in shares of Palomar during the 4th quarter valued at about $33,000. Finally, Rockefeller Capital Management L.P. boosted its stake in shares of Palomar by 81.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company's stock valued at $40,000 after purchasing an additional 132 shares in the last quarter. Hedge funds and other institutional investors own 90.25% of the company's stock.

Palomar Company Profile

Palomar Holdings, Inc NASDAQ: PLMR is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.